Insider Selling: Humana Inc. (NYSE:HUM) Insider Sells 3,957 Shares of Stock

Humana Inc. (NYSE:HUMGet Rating) insider Samir Deshpande sold 3,957 shares of the company’s stock in a transaction dated Tuesday, May 3rd. The shares were sold at an average price of $434.19, for a total transaction of $1,718,089.83. Following the sale, the insider now directly owns 5,529 shares in the company, valued at $2,400,636.51. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of HUM opened at $442.34 on Thursday. The firm has a market cap of $55.95 billion, a P/E ratio of 18.77, a P/E/G ratio of 1.28 and a beta of 0.86. The stock has a 50 day simple moving average of $441.77 and a two-hundred day simple moving average of $435.25. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.53 and a quick ratio of 1.53. Humana Inc. has a 1 year low of $351.20 and a 1 year high of $475.44.

Humana (NYSE:HUMGet Rating) last issued its earnings results on Wednesday, April 27th. The insurance provider reported $8.04 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $6.79 by $1.25. The business had revenue of $23.97 billion during the quarter, compared to analyst estimates of $23.54 billion. Humana had a return on equity of 17.27% and a net margin of 3.51%. Humana’s revenue for the quarter was up 16.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $7.67 earnings per share. On average, equities analysts anticipate that Humana Inc. will post 24.65 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Friday, July 29th. Shareholders of record on Thursday, June 30th will be paid a $0.7875 dividend. This represents a $3.15 annualized dividend and a yield of 0.71%. The ex-dividend date is Wednesday, June 29th. Humana’s dividend payout ratio is currently 13.36%.

Several equities research analysts have commented on HUM shares. SVB Leerink dropped their price objective on shares of Humana from $528.00 to $525.00 and set an “outperform” rating on the stock in a report on Thursday, February 3rd. Barclays dropped their price objective on shares of Humana from $540.00 to $490.00 and set an “overweight” rating on the stock in a report on Friday, January 7th. Deutsche Bank Aktiengesellschaft upped their price objective on shares of Humana from $418.00 to $435.00 in a report on Thursday, February 3rd. Zacks Investment Research upgraded Humana from a “sell” rating to a “hold” rating and set a $445.00 price target on the stock in a research report on Friday, February 4th. Finally, Morgan Stanley upped their price target on Humana from $410.00 to $436.00 and gave the company an “equal weight” rating in a research report on Wednesday, March 9th. Seven analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Humana currently has an average rating of “Buy” and an average target price of $486.28.

Institutional investors and hedge funds have recently modified their holdings of the business. Bell Investment Advisors Inc purchased a new stake in Humana in the third quarter worth approximately $26,000. Spire Wealth Management purchased a new stake in shares of Humana during the fourth quarter valued at approximately $30,000. BerganKDV Wealth Management LLC boosted its stake in shares of Humana by 885.7% during the fourth quarter. BerganKDV Wealth Management LLC now owns 69 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 62 shares during the period. Riverview Trust Co purchased a new stake in shares of Humana during the first quarter valued at approximately $32,000. Finally, Selective Wealth Management Inc. purchased a new stake in shares of Humana during the fourth quarter valued at approximately $35,000. 94.93% of the stock is owned by institutional investors and hedge funds.

About Humana (Get Rating)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Articles

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.